Category: Intellectual property
-
Spin-Off Creates Enzyme to Prevent Celiac Disease
A spin-off enterprise from University of Washington is developing a synthetic enzyme that prevents dietary gluten from triggering symptoms of celiac disease.
-
Cell Biotech Gains Organoid Technology
A Canadian biotechnology enterprise is licensing a technology that generates organoids, three-dimensional clusters of cells from stem cells that can form into gastrointestinal organs.
-
Patent Awarded for Whooping Cough Antibodies
An experimental treatment for pertussis, also known as whooping cough, using engineered humanized antibodies received a patent in the U.S.
-
Start-Up Developing Nanotech Bone Repairs
An enterprise formed earlier this year is licensing an engineered bone tissue repair technology that mixes ultrafine diamond particles with biocompatible polymers.
-
LEDs Shown to Reduce Alzheimer’s Brain Plaques
Pulsating LED lights were shown in lab mice to reduce amyloid-beta plaque deposits associated with Alzheimer’s disease on brain cells, with the lead researchers starting a company to commercialize the technology.
-
Start-Up Reprogramming Stem Cells to Treat Heart Failure
A new enterprise, spun-off from the Gladstone Institutes in San Francisco, plans to regenerate heart muscle from other cells to treat heart failure.
-
Biotech to Earn Up to $1 Billion from Synthetic Peptides
A biotechnology enterprise designing synthetic peptides to treat a range of diseases could gain up to $1 billion or more in a licensing deal with the pharmaceutical company AstraZeneca.
-
Company Launches to Discover Gut-Brain Therapies
A California Institute of Technology biologist is starting a new enterprise to discover treatments for neurological disorders through pathways originating in the gut.
-
Blood Stem Cell Start-Up Launches, Earns $48.5M Funding
A new enterprise, spun-off from Harvard University stem cell labs, aims to make stem cell transplants from bone marrow safer and more reliable.
-
Patent Awarded for Cancer-Fighting Antibody
A synthetic engineered antibody developed by MabVax Therapeutics that binds to solid tumor cells for cancer diagnostics and treatment received a U.S. patent.